This document provides a resume for Kirsten Anice Messick. It summarizes her experience as a senior supervisor with over 11 years of experience in the pharmaceutical industry, supervising pre-clinical studies. She has extensive experience conducting in-vivo studies, developing protocols, and training others. She received a Bachelor's degree in Pharmacology and Immunology from Monash University in Australia and holds several certifications related to laboratory animal handling and veterinary assisting. Her roles at Genentech included supervising research associates, scheduling studies, developing animal models, and writing preclinical protocols.
I would describe myself as a conscientious worker, problem solver and a dependable team player with laboratory expertise in molecular cloning, virology and immunology. I am proficient at developing small animal infection models, mammalian cell culture, proficient at working in Biosafety level -2 and 3 laboratories, developing recombinant gene constructs through primer design, restriction digestion and bacterial cloning. I am proficient at nucleic acid (DNA/RNA) extraction, quantitative PCR and RT-PCR. My technical expertise in virology and immunology include performing plaque assays and foci forming assays to quantify viremia and ELISA. I possess extensive training in working with laboratory animals and I am proficient at intra-nasal and intra-peritoneal drug administration, working with animal restraint systems like the In-TOX system and have performed nebulization studies using guinea pigs in the past. I also perform tail DNA genotyping in mice.
Alternate animal experiments models for pre and post clinical screening of new drugs.
#Expetrimental_Pharmacology.
#Preclinical Screening methods and testing models.
#Animal_Handeling
Maternal curcumin exposure causes fetal gross morphological anomalies and ske...Innspub Net
Curcumin is a phenolic compound extracted from the rhizome of turmeric (Curcuma longa L.). Although declared as safe for human consumption, curcumin has been found to be embryotoxic in some organisms indicating its potential as a teratogen. In this study, the teratogenic effect of maternal curcumin exposure in mouse fetuses was evaluated. Three experimental groups of pregnant mice were treated with 1.05, 1.52, and 2.0 mg/g body weight/day 95% curcumin, respectively, from gestation day (GD) 6 to 15. A fourth group without curcumin exposure served as a control. At GD18, the mice were sacrificed and the total number of implanted embryos including resorbed, dead, and live fetuses were counted for litter analysis. Extracted fetuses were also analyzed for gross morphological anomalies and subsequently have undergone alizarin staining for the visualization of skeletal malformations. Results showed an increased resorption rate in the 2.0 mg/g treatment (p<0.001). There is also a reduction of fetal weight (p<0.001) and crown-rump length (p<0.001) in a dose-dependent manner. Gross morphological analysis shows cranio-facial malformations such as flattened nose bridge (p<0.05) and micrognathia (p<0.05) in 2.0 mg/g treatment. Skeletal malformations such as large anterior fontanelle (p<0.001), misaligned ossification centers in the sternum (p<0.001), and delayed ossification in the forepaws, hind paws, and caudal vertebrae (p<0.001) were also observed at 2.0 mg/g treatment. Meanwhile, the presence of supernumerary ribs is not statistically different in the four groups. The results indicate that curcumin is teratogenic in mouse fetuses due to observed gross morphological anomalies and skeletal malformations.
DOC2 - No significant risk levels 4 MI - CaliforniaToxiColaOrg
Esta es la propuesta que está presentando la Oficina de Riesgos Ambientales en la Salud de la Agencia de Protección Ambiental de California para establecer un nivel máximo de ingesta diaria de 4-Metilidimadazol (compuesto cancerígeno que se encuentra en el Caramelo IV utilizado en las bebidas de Cola) que no signifique riesgo a la salud. La propuesta de la autoridad en California es que no se consuma más de 16 microgramos de este compuesto en todo un día. Como se ve en el DOC3, la cantidad de 4-Metilidimadazol que se encuentra en una lata de bebida de cola puede ser 8 veces más de este límite.
I would describe myself as a conscientious worker, problem solver and a dependable team player with laboratory expertise in molecular cloning, virology and immunology. I am proficient at developing small animal infection models, mammalian cell culture, proficient at working in Biosafety level -2 and 3 laboratories, developing recombinant gene constructs through primer design, restriction digestion and bacterial cloning. I am proficient at nucleic acid (DNA/RNA) extraction, quantitative PCR and RT-PCR. My technical expertise in virology and immunology include performing plaque assays and foci forming assays to quantify viremia and ELISA. I possess extensive training in working with laboratory animals and I am proficient at intra-nasal and intra-peritoneal drug administration, working with animal restraint systems like the In-TOX system and have performed nebulization studies using guinea pigs in the past. I also perform tail DNA genotyping in mice.
Alternate animal experiments models for pre and post clinical screening of new drugs.
#Expetrimental_Pharmacology.
#Preclinical Screening methods and testing models.
#Animal_Handeling
Maternal curcumin exposure causes fetal gross morphological anomalies and ske...Innspub Net
Curcumin is a phenolic compound extracted from the rhizome of turmeric (Curcuma longa L.). Although declared as safe for human consumption, curcumin has been found to be embryotoxic in some organisms indicating its potential as a teratogen. In this study, the teratogenic effect of maternal curcumin exposure in mouse fetuses was evaluated. Three experimental groups of pregnant mice were treated with 1.05, 1.52, and 2.0 mg/g body weight/day 95% curcumin, respectively, from gestation day (GD) 6 to 15. A fourth group without curcumin exposure served as a control. At GD18, the mice were sacrificed and the total number of implanted embryos including resorbed, dead, and live fetuses were counted for litter analysis. Extracted fetuses were also analyzed for gross morphological anomalies and subsequently have undergone alizarin staining for the visualization of skeletal malformations. Results showed an increased resorption rate in the 2.0 mg/g treatment (p<0.001). There is also a reduction of fetal weight (p<0.001) and crown-rump length (p<0.001) in a dose-dependent manner. Gross morphological analysis shows cranio-facial malformations such as flattened nose bridge (p<0.05) and micrognathia (p<0.05) in 2.0 mg/g treatment. Skeletal malformations such as large anterior fontanelle (p<0.001), misaligned ossification centers in the sternum (p<0.001), and delayed ossification in the forepaws, hind paws, and caudal vertebrae (p<0.001) were also observed at 2.0 mg/g treatment. Meanwhile, the presence of supernumerary ribs is not statistically different in the four groups. The results indicate that curcumin is teratogenic in mouse fetuses due to observed gross morphological anomalies and skeletal malformations.
DOC2 - No significant risk levels 4 MI - CaliforniaToxiColaOrg
Esta es la propuesta que está presentando la Oficina de Riesgos Ambientales en la Salud de la Agencia de Protección Ambiental de California para establecer un nivel máximo de ingesta diaria de 4-Metilidimadazol (compuesto cancerígeno que se encuentra en el Caramelo IV utilizado en las bebidas de Cola) que no signifique riesgo a la salud. La propuesta de la autoridad en California es que no se consuma más de 16 microgramos de este compuesto en todo un día. Como se ve en el DOC3, la cantidad de 4-Metilidimadazol que se encuentra en una lata de bebida de cola puede ser 8 veces más de este límite.
Reversible Antifertility Effect of Cassia tora Linn in Male Rats
Samiya Khan, Pratap Chand Mali*
*Address for Correspondence: Dr. Pratap Chand Mali, Associate Professor, Reproductive Biomedicine and Natural Products Lab, Centre for Advanced Studies, Department of Zoology, University of Rajasthan, Jaipur, India
ABSTRACT- Background: Plant Cassia tora has been used in traditional and modern medicines for different pharmacological activities.
Objectives: The present investigation has been taken to observe and evaluate effects of Cassia tora on the reproduction functions of male rats in search a safe, orally effective and reversible fertility regulating agent.
Materials and Methods: Fifty percent ethanolic extract of Cassia tora was prepared and administered orally in male Wistar rats at the doses of 50, 100 and 200 mg/kg.b.wt./rat/day dose levels respectively for a period of 60 days and some of the treated rats were kept 30 days for recovery of fertility to assessed reversibility effects. Hematological indices, serum clinical investigations were also performed to assess toxic effects if any caused in rats by treatment. Proteins, cholesterol, glycogen, ascorbic acid, sialic acid and fructose level were analyzed in rats. Serum FSH, LH and Testosterone levels were measure. Rats were castrated to evaluate effects on reproductive functions of hormones and mode of action of the Cassia tora treatment. For histopathological observations tissues were fixed in Bouin’s fluid, dehydrated, sectioned and stained with Hematoxylin and Eosin.
Results: Treatment of Cassia tora significantly reduced the weights of testes and accessory sex organs. Sperm density and motility were declined high significantly. Levels of Testosterone and FSH hormone were significantly decreased in rats. The protein, sialic acid, fructose, ascorbic acid and glycogen contents of reproductive accessory sex organs were decreased significantly. Germinal epithelium of testes degenerated and number of spermatocytes, spermatids and spermatozoa in lumen of seminiferous tubules reduced.
Conclusions: The decreased testes and accessory sex organs weights, sperm motility, density and testosterone level in rats might be due to androgen suppression effects of Cassia tora treatment cause inhibition of spermatogenesis resulted reduction of fertility in treated male rats.
Key-words- Cassia tora, Contraception, Fertility, Sperm motility, Sperm density, Male rat
Structurally characterized arabinogalactan from Anoectochilus formosanus as a...Cây thuốc Việt
In this study, the innate immuno-modulatory effects and anti-cancer action of arabinogalactan (AG), a derivative of a well-known orchid, Anoectochilus formosanus, were investigated. The innate immunomodulatory effects of AG were determined in vitro using RAW 264.7 cells for microarray analysis, and in vivo using BALB/c mice administrated with AG at 5 and 15 mg/kg intra-peritoneally for 3 weeks. The anti-cancer activity of AG was evaluated by CT26 colon cancer-bearing BALB/c mice. The microarray
analysis was performed to evaluate the innate immunity and demonstrated that AG significantly induced the expression of cytokines, chemokines, and co-stimulatory receptors, such as IL-1, CXCL2, and CD69.
An intraperitoneal injection of AG in mice increased the spleen weight, but not the body weight. The treatment of mitogen, LPS significantly stimulated splenocyte proliferation in AG treated groups. The AG treatment also promoted splenocyte cytotoxicity against YAC-1 cells and increased the percentage
of CD3+CD8+ cytotoxic T cells in innate immunity test. Our experiments revealed that AG significantly decreased both tumour size and tumour weight. Besides, AG increased the percentage of DC, CD3+CD8+ T cells, CD49b+CD3− NK cells among splenocytes, and cytotoxicity activity in tumour-bearing mice. In addition, the immunohistochemistry of the tumour demonstrated that the AG treatments increased the tumour-filtrating NK and cytotoxic T-cell. These results demonstrated that AG, a polysaccharide derived
from a plant source, has potent innate immuno-modulatory and anti-cancer activity. AG may therefore be used for cancer immunotherapy.
dkNET Webinar: Population-Based Approaches to Investigate Endocrine Communica...dkNET
Abstract
Mechanisms of inter-organ signaling have been established as hallmarks of nearly every pathophysiologic condition, where many exist as related and complex diseases. While significant work has been focused on understanding how individual cell types contribute and respond to specific perturbations related to common, complex disease, an equally-important but relatively less-explored question involves how relationships between organs are altered in the context of an integrated living organism. Current technical advances, such as proteomic analysis of plasma or conditioned media, have allowed for a more unbiased visualization and discovery of additional inter-tissue signaling molecules. However, one important feature which is lacking from these approaches is the ability to gain insight as to the function, mechanisms of action and target tissue(s) of relevant molecules. To begin to address these constraints, we initially developed a correlation-based bioinformatics framework which uses multi-tissue gene expression and/or proteomic data, as well as publicly available resources to statistically rank and functionally annotate endocrine proteins involved in tissue cross-talk. Using this approach, we identified many known and experimentally validated several novel inter-tissue circuits. This was this first study to directly link an endocrine-focused bioinformatics pipeline from population data directly to experimentally-validated mechanisms of inter-tissue communication. While these validations provide strong support for exploiting natural variation to discover new modes of communication, these serve as simple proof-of-principle studies and, thus, have promising potential for expansion. Some of these will be discussed during the presentation.
Presenter: Marcus Seldin, Ph.D. Assistant Professor, Biological Chemistry, University of California Irvine
Upcoming webinars schedule: https://dknet.org/about/webinar
Objective: To evaluate the results of the effect of nebivolol on tibial bone defect and graft application in new bone development in the rat.
Study Design: Thirty Wistar albino rats were divided into 3 groups. In the Control group, tibia bone defect was created without any treatment. In the Defect+ Graft group, allograft treatment was performed by forming a 6 mm tibial bone defect. In the Defect+Graft+ Nebivolol group, alloplastic bone graft was placed in the calvarial bone defect and then nebivolol (0.34 mg/mL solution/day) treatment was intraperitoneally applied for 28 days.
Results: Histopathological examination revealed inflammation in the defect area, congestion in the vessels, degeneration in collagen fibers, and an increase in osteoclast cells. There was an increase in inflammation and blood vessel structure in graft application, and osteoblastic activity matrix formation after reorganization nebivolol application in collagen fibers. Osteonectin expression was positive in the collagen fiber and matrix, starting in the Graft group, in osteoblasts, whereas in the Nebivolol group, osteoblasts increased in osteocytes and new bone formation.
Conclusion: Nebivolol is thought to have a positive effect on osteoinductive bone growth factors and contribute to the cell-matrix interaction, in addition to the supporting effect of the graft with its antioxidative effect.
Keywords: allograft; bone; bone regeneration; disease models, animal; nebivolol; orthopedic procedures; osteonectin; rats; tibia; tibial defect
Reversible Antifertility Effect of Cassia tora Linn in Male Rats
Samiya Khan, Pratap Chand Mali*
*Address for Correspondence: Dr. Pratap Chand Mali, Associate Professor, Reproductive Biomedicine and Natural Products Lab, Centre for Advanced Studies, Department of Zoology, University of Rajasthan, Jaipur, India
ABSTRACT- Background: Plant Cassia tora has been used in traditional and modern medicines for different pharmacological activities.
Objectives: The present investigation has been taken to observe and evaluate effects of Cassia tora on the reproduction functions of male rats in search a safe, orally effective and reversible fertility regulating agent.
Materials and Methods: Fifty percent ethanolic extract of Cassia tora was prepared and administered orally in male Wistar rats at the doses of 50, 100 and 200 mg/kg.b.wt./rat/day dose levels respectively for a period of 60 days and some of the treated rats were kept 30 days for recovery of fertility to assessed reversibility effects. Hematological indices, serum clinical investigations were also performed to assess toxic effects if any caused in rats by treatment. Proteins, cholesterol, glycogen, ascorbic acid, sialic acid and fructose level were analyzed in rats. Serum FSH, LH and Testosterone levels were measure. Rats were castrated to evaluate effects on reproductive functions of hormones and mode of action of the Cassia tora treatment. For histopathological observations tissues were fixed in Bouin’s fluid, dehydrated, sectioned and stained with Hematoxylin and Eosin.
Results: Treatment of Cassia tora significantly reduced the weights of testes and accessory sex organs. Sperm density and motility were declined high significantly. Levels of Testosterone and FSH hormone were significantly decreased in rats. The protein, sialic acid, fructose, ascorbic acid and glycogen contents of reproductive accessory sex organs were decreased significantly. Germinal epithelium of testes degenerated and number of spermatocytes, spermatids and spermatozoa in lumen of seminiferous tubules reduced.
Conclusions: The decreased testes and accessory sex organs weights, sperm motility, density and testosterone level in rats might be due to androgen suppression effects of Cassia tora treatment cause inhibition of spermatogenesis resulted reduction of fertility in treated male rats.
Key-words- Cassia tora, Contraception, Fertility, Sperm motility, Sperm density, Male rat
Structurally characterized arabinogalactan from Anoectochilus formosanus as a...Cây thuốc Việt
In this study, the innate immuno-modulatory effects and anti-cancer action of arabinogalactan (AG), a derivative of a well-known orchid, Anoectochilus formosanus, were investigated. The innate immunomodulatory effects of AG were determined in vitro using RAW 264.7 cells for microarray analysis, and in vivo using BALB/c mice administrated with AG at 5 and 15 mg/kg intra-peritoneally for 3 weeks. The anti-cancer activity of AG was evaluated by CT26 colon cancer-bearing BALB/c mice. The microarray
analysis was performed to evaluate the innate immunity and demonstrated that AG significantly induced the expression of cytokines, chemokines, and co-stimulatory receptors, such as IL-1, CXCL2, and CD69.
An intraperitoneal injection of AG in mice increased the spleen weight, but not the body weight. The treatment of mitogen, LPS significantly stimulated splenocyte proliferation in AG treated groups. The AG treatment also promoted splenocyte cytotoxicity against YAC-1 cells and increased the percentage
of CD3+CD8+ cytotoxic T cells in innate immunity test. Our experiments revealed that AG significantly decreased both tumour size and tumour weight. Besides, AG increased the percentage of DC, CD3+CD8+ T cells, CD49b+CD3− NK cells among splenocytes, and cytotoxicity activity in tumour-bearing mice. In addition, the immunohistochemistry of the tumour demonstrated that the AG treatments increased the tumour-filtrating NK and cytotoxic T-cell. These results demonstrated that AG, a polysaccharide derived
from a plant source, has potent innate immuno-modulatory and anti-cancer activity. AG may therefore be used for cancer immunotherapy.
dkNET Webinar: Population-Based Approaches to Investigate Endocrine Communica...dkNET
Abstract
Mechanisms of inter-organ signaling have been established as hallmarks of nearly every pathophysiologic condition, where many exist as related and complex diseases. While significant work has been focused on understanding how individual cell types contribute and respond to specific perturbations related to common, complex disease, an equally-important but relatively less-explored question involves how relationships between organs are altered in the context of an integrated living organism. Current technical advances, such as proteomic analysis of plasma or conditioned media, have allowed for a more unbiased visualization and discovery of additional inter-tissue signaling molecules. However, one important feature which is lacking from these approaches is the ability to gain insight as to the function, mechanisms of action and target tissue(s) of relevant molecules. To begin to address these constraints, we initially developed a correlation-based bioinformatics framework which uses multi-tissue gene expression and/or proteomic data, as well as publicly available resources to statistically rank and functionally annotate endocrine proteins involved in tissue cross-talk. Using this approach, we identified many known and experimentally validated several novel inter-tissue circuits. This was this first study to directly link an endocrine-focused bioinformatics pipeline from population data directly to experimentally-validated mechanisms of inter-tissue communication. While these validations provide strong support for exploiting natural variation to discover new modes of communication, these serve as simple proof-of-principle studies and, thus, have promising potential for expansion. Some of these will be discussed during the presentation.
Presenter: Marcus Seldin, Ph.D. Assistant Professor, Biological Chemistry, University of California Irvine
Upcoming webinars schedule: https://dknet.org/about/webinar
Objective: To evaluate the results of the effect of nebivolol on tibial bone defect and graft application in new bone development in the rat.
Study Design: Thirty Wistar albino rats were divided into 3 groups. In the Control group, tibia bone defect was created without any treatment. In the Defect+ Graft group, allograft treatment was performed by forming a 6 mm tibial bone defect. In the Defect+Graft+ Nebivolol group, alloplastic bone graft was placed in the calvarial bone defect and then nebivolol (0.34 mg/mL solution/day) treatment was intraperitoneally applied for 28 days.
Results: Histopathological examination revealed inflammation in the defect area, congestion in the vessels, degeneration in collagen fibers, and an increase in osteoclast cells. There was an increase in inflammation and blood vessel structure in graft application, and osteoblastic activity matrix formation after reorganization nebivolol application in collagen fibers. Osteonectin expression was positive in the collagen fiber and matrix, starting in the Graft group, in osteoblasts, whereas in the Nebivolol group, osteoblasts increased in osteocytes and new bone formation.
Conclusion: Nebivolol is thought to have a positive effect on osteoinductive bone growth factors and contribute to the cell-matrix interaction, in addition to the supporting effect of the graft with its antioxidative effect.
Keywords: allograft; bone; bone regeneration; disease models, animal; nebivolol; orthopedic procedures; osteonectin; rats; tibia; tibial defect
1. Kirsten Anice Messick
8625 Briarwood Lane, Dublin, CA 94568, (925) 828-5236 E-mail: kmessick@gene.com
Experienced senior supervisor with over 11 years in the pharmaceutical industry.
Extensive hands-on experience with in-vivo study conduct, protocol creation and bio method
training. Currently supervising 4 direct reports and working within a team of 20 scientific
researchers supporting internal toxicology, pharmacokinetic and pharmacodynamic
biomarker pre-clinical studies.
Education/Certification:
Bachelor of Science with an emphasis in Pharmacology & Immunology, 1997
Monash University, Melbourne, Australia
Laboratory Animal Technician – AALAS certified, 2005
St. Johns Ambulance Level II Course in Basic First Aid, Melbourne, Australia, 2003
Certificate II in Animal Handling, International Correspondence School, NSW, Australia, 1999
Surgical Assisting Course for Veterinary Technicians, University of California Davis,
California, 1998
Continuing Education Course for Veterinary Technicians, Veterinary Learning Systems,
California, 1997
Key Accomplishments:
Supervisor II
Liaison between the DMPK department and In Vivo Studies Group resulting in the scheduling of
450 in vivo studies/year
Design and implementation of mouse hemolyzed blood sampling model to reduce animal usage
on in house pharmacokinetic studies
Contributed to the design of a new study request system for in house small molecule
pharmacokinetic studies (SMDI in vivo scheduler)
Participation on internal formulation advisory board assisting in and conducting in vivo studies to
establish recommended no-observed-effect-level (NOEL) and maximum tolerated dose (MTD) for
several commonly used intravenous solvents in the CD-1 mouse
Design and implementation of the IV infusion model in MRSA infected mice
Completed the 6 week Toxicology immersion (cross-training strategy) to gain proficiency in all
aspects of study execution
Liaison between BASi and the IVS Group to schedule and conduct bi-annual maintenance of the
Culex automated blood sampling machines
Employment History:
Supervisor II Genentech, Inc., South San Francisco, CA (Safety Assessment Department)
(10/2012 – present)
Act as a study coordinator on pharmacokinetic and toxicology small molecule
in vivo studies. Direct supervision of 4 Research Associates. Supervisory tasks involve:
training, assisting in goal setting & development planning, conducting performance reviews,
ensuring compliance. Act as a liaison between the DMPK department and In Vivo Studies
group, scheduling small molecule PK studies and assigning study coordinators. Schedule
studies so as to ensure project timelines and needs are met as well as to maintain proper
workload balance among in vivo personnel. Perform applicable techniques in common
laboratory animal species, as mentioned above. Develop animal models, write preclinical
protocols and order animals.
2. Supervisor I Genentech, Inc., South San Francisco, CA (Safety Assessment Department)
(08/2008 – 10/2012)
Act as a study coordinator on pharmacokinetic and toxicology small molecule
in vivo studies. Direct supervision of 3 Research Associates. Supervisory tasks involve:
training, assisting in goal setting & development planning, conducting performance reviews,
ensuring compliance. Act as a liaison between the DMPK department and In Vivo Studies
Group, scheduling small molecule PK studies and assigning study coordinators. Schedule
studies so as to ensure project timelines and needs are met as well as to maintain proper
workload balance among in vivo personnel. Perform applicable techniques in common
laboratory animal species, as mentioned above. Develop animal models, write preclinical
protocols, order animals and act as a mentor.
Research Associate Genentech, Inc., South San Francisco, CA (PKPDS Department)
(07/2004 – 07/2008)
Assist the Pharmacokinetic/Pharmacodynamic Sciences and Drug Metabolism Departments
with the technical conduct of in vivo studies. Perform applicable techniques in common
laboratory animal species, as mentioned above. Develop animal models, write preclinical
protocols and assume role of study coordinator as appropriate.
Senior Research Assistant University of Melbourne, Melbourne, Australia (Pharmacology
Department) (02/2002 – 04/2004)
Assist the Clinical and Experimental Pharmacology Departments with the technical conduct
of in vivo studies. Perform applicable techniques in common laboratory animal species, as
mentioned above.
Veterinary Technician Bishop Ranch Veterinary Hospital, San Ramon, CA
(02/2000 – 02/2001)
Assisted veterinarians during surgical procedures with anesthesia induction, monitoring and
animal recovery. Performed dental cleaning & extractions, catheter placement for IV fluid
administration, blood sample collection from the jugular and cephalic veins and basic wound
care in cats and dogs.
Veterinary Technician Brandon Park Veterinary Hospital, Melbourne, Australia
(09/1998 – 01/2001)
Assisted veterinarians during surgical procedures with anesthesia induction, monitoring and
animal recovery. Performed dental cleaning & extractions, catheter placement for IV fluid
administration, blood sample collection from the jugular & cephalic veins and basic wound
care in cats and dogs. Served as a client liaison. Tasks included answering phone calls,
scheduling appointments, advising clients on basic pet care and recommending health care
products as needed.
Veterinary Technician Norris Canyon Veterinary Medical Centre, San Ramon, CA
(02/1997 – 08/1998)
Assisted veterinarians during surgical procedures with anesthesia induction, monitoring and
animal recovery. Performed dental cleaning & extractions, catheter placement for IV fluid
administration, blood sample collection from the jugular & cephalic veins and basic wound
care in cats and dogs. Served as a client liaison. Tasks included answering phone calls,
scheduling appointments, advising clients on basic pet care and recommending health care
products as needed.
Lab Skills:
Animal Restraint (mouse, rat, rabbit, guinea pig)
Drug Administration – IP (mouse, rat), IV (rat, mouse, rabbit, dog, cat), SC (rat, mouse, rabbit,
guinea pig, dog, cat), IM (rabbit, guinea pig, cat, dog), Oral gavage (mouse, rat, cat, dog),
continuous IV infusion (mouse, rat)
3. Blood Collection – orbital bleed & cardiac stick (mouse, rat guinea pig), via marginal ear vein &
cardiac stick (rabbit), via cannula, lateral tail vein, cardiac stick, orbital bleed & Culex automated
blood sampler (rat)
CSF collection – (mouse, rat)
Brain microdialysis – (rat) both small and large molecules
Cannulation Surgeries – jugular & femoral vein (rat), jugular vein (mouse)
Aortic flow probe insertion (rabbit) for chronic cardiovascular studies
L4/L5 ligation - (rat) to induce neuropathy
Catheter Insertion – arterial and venous (rabbit)
Behavioural testing – tail flick, hot plate, von frey fibres/allodynia (mouse, rat)
Whole Body Perfusion (mouse, rat, guinea pig)
Anesthesia/Euthanasia (mouse, rat, guinea pig, rabbit)
Organ/lymph node collection (mouse, rat, guinea pig)
Work with Radioisotopes (I-125/131, 3H, C14, In-111, Rb-86, Tc99), Cytotoxins, Armed
Antibodies (maytansenoids, auristatins), Infectious agents (influenza, MRSA)
Work with Provantis for toxicology studies
Whole rabbit perfusion/fixation for radiographic analysis of bone density and collateral vessel
formation
Publications:
Choo EF, Woolsey S, DeMent K, Ly J, Messick K, Qin A, Takahashi R. (2015). Use of
transgenic mouse models to understand the oral disposition and drug-drug interaction potential of
cobimetinib, a MEK inhibitor. Drug Metab Dispos, 43(6), 864-8699.
Poullin P, Chen YH, Ding X, Gould SE, Hop CE, Messick K,
Oeh J, Liederer BM. (2015). Prediction of drug distribution in subcutaneous xenografts of
human tumor cell lines and healthy tissues in mouse: application of the tissue composition-based model
to neoplastic drugs. J Pharm Sci, 104(4), 1508-1521.
Choo EF, Ly J, Chan J, Shahidi-Latham SK, Messick K, Plise E, Quiason CM, Yang L. (2014). Role of P-
glycoprotein on the brain penetration and brain pharmacodynamics activity of the MEK inhibitor
cobimetinib. Mol. Pharm, 3;11(11), 4199-4207.
Chang JH, Ly J, Plise E, Zhang X, Mesick K, Wright M, Cheong J. (2014). Differential effects of Rifampin
and Ketoconazole on the blood and liver concentration of atorvastatin in wild- type and Cyp3a and
Oatp1a/b knockout mice. Drug Metab Dispos, 42(6), 1067-1073.
Liang X, Yang L, Qin AR, Ly J, Liederer BM, Messick K, Ma S, Zak M, Dragovich PS, Dean BJ, Hop CE,
Deng Y. (2014). Measuring NAD(+) levels in mouse blood and tissue samples via a surrogate matrix
approach using LC-MS/MS. Bioanalysis, 6(11), 1445-1457.
Thackaberry EA, Wang X, Schweiger M, Messick K, Valle N, Dean B, Sambrone A, Bowman T, Xie M.
(2014). Solvent-based formulations for intravenous mouse pharmacokinetic studies: tolerability and
recommended solvent dose limits. Xenobiotica, 44(3), 235-241.
Khojasteh SC, Yue Q, Ma S, Castanedo G, Chen JZ, Lyssikatos J, Mulder T, Takahashi R, Ly J, Messick
K, Jia W, Liu L, Hop CE, Wong H. (2014). Investigations into the mechanisms of pyridine ring cleavage in
vismodegib. Drug Metab Dispos, 42(3), 343-351.
Boggs JW, Hop CE, McNamara E, Deng Y, Messick K, West K, Choo EF. (2014). Assessment of the
Hepatic CYP Reductase Null Mouse Model and its Potential Application in Drug Discovery Mol Pharm,
11(3), 1062-1068.
4. Author, A.A.. (Publication Year). Article title. Periodical Title, Volume(Issue), pp.-pp.
APA format example:
Nevin, A. (1990). The changing of teacher education special education. Teacher Education
and Special Education: The Journal of the Teacher Education Division of the Council for
Exceptional Children, 13(3-4), 147-148.